About Schizophrenia
Schizophrenia is a chronic brain disorder that severely affects the quality of life of a patient by disturbing the normal functioning of the brain. Psychotic symptoms and a diminished range of expression of emotions are the characteristics of schizophrenia. The exact etiology of schizophrenia is still not known. In men, it appears in the late teens or early 20s, and in women in the late 20s or early 30s. However, most of the symptoms of this disorder can be managed with medication and psychological help.
TechNavio's analysts forecast the Global Schizophrenia Therapeutics market to grow at a CAGR of 2.82 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Schizophrenia Therapeutics market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of schizophrenia that are available in the market. The Global Schizophrenia Therapeutics market can be segmented into two: First-generation Antipsychotics and Second-generation Antipsychotics.
TechNavio's report, the Global Schizophrenia Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Schizophrenia Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• Bristol-Myers Squibb
• Eli Lily
• F. Hoffmann-La Roche
• H. Lundbeck
• Johnson & Johnson
• Otsuka Pharmaceuticals
• Pfizer
• Sumitomo Dainippon Pharma
Other Prominent Vendors
• Abbott Laboratories
• Acadia Pharmaceuticals
• Alkermes
• Astellas Pharma
• Chugai Pharmaceutical
• Glaxo Smith Kline
• Merck
• Mitsubishi Tanabe Pharma
• Novartis
• Takeda Pharmaceutical
Market Driver
• Increase in Aging Population
• For a full, detailed list, view our report
Market Challenge
• Increase in Generic Competition
• For a full, detailed list, view our report
Market Trend
• Rising Awareness of Schizophrenia
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Schizophrenia Therapeutics Market in the US
06.3.1 Market Size and Forecast
06.4 Five Forces Analysis
07. Pipeline Snapshot
08. Rate of Incidence and Prevalence
08.1.1 US
09. Types of Schizophrenia
10. Phases of Schizophrenia
11. Market Segmentation by Drug Class
12. Geographical Segmentation
12.1 Schizophrenia Therapeutics Market in Americas
12.1.1 Market Size and Forecast
12.2 Schizophrenia Therapeutics Market in the APAC Region
12.2.1 Market Size and Forecast
12.3 Schizophrenia Therapeutics Market in the EMEA Region
12.3.1 Market Size and Forecast
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 AstraZeneca
21.1.1 Key Facts
21.1.2 Business Description
21.1.3 Business Segmentation
21.1.4 Business Strategy
21.1.5 Revenue by Business Segmentation
21.1.6 Revenue Comparison 2011-2013
21.1.7 Sales Revenue by Geographical Segmentation
21.1.8 Key Developments
21.1.9 SWOT Analysis
21.2 Bristol-Myers Squibb Co.
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Product Segmentation
21.2.4 Sales by Geography
21.2.5 Business Strategy
21.2.6 Key Information
21.2.7 SWOT Analysis
21.3 Eli Lilly and Co.
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2013
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Business Strategy
21.3.7 Key Developments
21.3.8 SWOT Analysis
21.4 F. Hoffmann-La Roche
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Geographical Segmentation by Revenue
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.5 H. Lundbeck
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Product Segmentation by Revenue 2013
21.5.4 Product Segmentation by Revenue 2012 and 2013
21.5.5 Geographical Segmentation by Revenue 2013
21.5.6 Business Strategy
21.5.7 Recent Developments
21.5.8 SWOT Analysis
21.6 Johnson & Johnson
21.6.1 Key Facts
21.6.2 Business Overview
21.6.3 Business Segmentation by Revenue 2013
21.6.4 Business Segmentation by Revenue 2012 and 2013
21.6.5 Geographical Segmentation by Revenue 2013
21.6.6 Business Strategy
21.6.7 Recent Developments
21.6.8 SWOT Analysis
21.7 Otsuka Pharmaceuticals
21.7.1 Key Facts
21.7.2 Business Overview
21.7.3 Business Segmentation by Revenue 2014
21.7.4 Business Segmentation by Revenue 2013 and 2014
21.7.5 Geographical Segmentation by Revenue 2014
21.7.6 Business Strategy
21.7.7 Recent Developments
21.7.8 SWOT Analysis
21.8 Pfizer Inc.
21.8.1 Key Facts
21.8.2 Business Description
21.8.3 Business Segmentation
21.8.4 Revenue by Business Segmentation
21.8.5 Revenue Comparison 2012 and 2013
21.8.6 Sales by Geography
21.8.7 Business Strategy
21.8.8 Key Developments
21.8.9 SWOT Analysis
21.9 Sumitomo Dainippon Pharma
21.9.1 Key Facts
21.9.2 Business Overview
21.9.3 Product Segmentation
21.9.4 Products Segmentation by Revenue 2013 and 2014
21.9.5 Business Strategy
21.9.6 Recent Developments
21.9.7 SWOT Analysis
22. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Schizophrenia Therapeutics Market 2013-2018 (US$ billion)
Exhibit 3: Schizophrenia Therapeutics Market in the US
Exhibit 4: Types of Schizophrenia
Exhibit 5: Phases of Schizophrenia
Exhibit 6: Global Schizophrenia Therapeutics Market Segmentation by Drug Class
Exhibit 7: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013
Exhibit 8: Schizophrenia Therapeutics Market in America 2013-2018 (US$ billion)
Exhibit 9: Schizophrenia Therapeutics Market in the APAC Region 2013-2018 (US$ billion)
Exhibit 10: Schizophrenia Therapeutics Market in the EMEA Region 2013-2018 (US$ billion)
Exhibit 11: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013-2018 (US$ billion)
Exhibit 12: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013-2018 (in percent)
Exhibit 13: Johnson & Johnson Sales by Therapeutic Area (Pharmaceuticals) 2013
Exhibit 14: AstraZeneca: Business Segmentation
Exhibit 15: AstraZeneca: Revenue by Business Segmentation 2013
Exhibit 16: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 17: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
Exhibit 18: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
Exhibit 19: Bristol-Myers Squibb Co.: Sales by Geography 2013
Exhibit 20: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 21: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 22: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 23: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 24: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 25: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
Exhibit 26: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
Exhibit 27: H. Lundbeck: Business Segmentation by Revenue 2013
Exhibit 28: H. Lundbeck: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 29: H. Lundbeck: Geographical Segmentation by Revenue 2013
Exhibit 30: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 31: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 32: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 33: Otsuka Pharmaceutical: Business Segmentation by Revenue 2014
Exhibit 34: Otsuka Pharmaceutical: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 35: Otsuka Pharmaceutical: Geographical Segmentation by Revenue 2014
Exhibit 36: Pfizer Inc.: Business Segmentation
Exhibit 37: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 38: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 39: Pfizer Inc.: Revenue by Geography 2013
Exhibit 40: Sumitomo Dainippon Pharma: Product Segmentation 2014
Exhibit 41: Sumitomo Dainippon Pharma: Product Segmentation by Revenue 2013 and 2014
